

1 Title: FCGR2A-131H/H is under-represented amongst patients with
2 primary immunodeficiencies

3

4 **Short running title (50 Chars): Role of FCGR variants in patients with PID**

5

6 Edward W D Flewitt¹, James E G Charlesworth^{2,3}, Smita Y Patel^{1,3}, Chantal E Hargreaves¹

7

8 ¹Nuffield Department of Medicine and Oxford NIHR Biomedical Research Centre, University of
9 Oxford, Oxford, OX3 9DU, UK.

10 ²Department of Paediatrics, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation
11 Trust, Oxford, OX3 9DU

12 ³Clinical Immunology Department, John Radcliffe Hospital, Oxford University Hospitals NHS
13 Foundation Trust, Oxford, OX3 9DU

14 Corresponding author: Smita Y Patel, email: smita.patel@ndm.ox.ac.uk

15

16 Abbreviations: CMC (chronic mucocutaneous candidiasis), CVID (common variable
17 immunodeficiency disorder), F (phenylalanine), FCGR (Fc gamma receptor), H (histidine), HWE
18 (Hardy-Weinberg equilibrium), I (isoleucine), ITP (immune thrombocytopenia purpura), PCR
19 (polymerase chain reaction), PID (primary immunodeficiencies), R (arginine), SLE (systemic lupus
20 erythematosus), SNP (single nucleotide polymorphism), T (threonine), V (valine)

21

22 Word count: 2978

23 Title heading: Human Immunology

24 Abstract

25 The Fc γ receptors (Fc γ Rs) act as modulators of the immune system and have previously been shown
26 to play a role in immune disorders such as systemic lupus erythematosus and immune
27 thrombocytopenic purpura. Thus far, their role in primary immunodeficiencies (PID), including
28 common variable immunodeficiency disorders (CVID), has not been studied. In this paper we
29 explored whether there is an association between the following single nucleotide polymorphisms
30 (SNPs) and CVID: *FCGR2A* H131R (rs1801274), *FCGR2B* I232T (rs1050501), and *FCGR3A* F158V
31 (rs396991). We compared the genotypes of a cohort of 83 patients with PID, including 56 with CVID,
32 against controls. We found a significant difference between our mixed PID cohort and controls at the
33 *FCGR2A* H131R SNP ($X^2 = 7.884$, $p = 0.019$). There was not a significant difference at either of the
34 other SNPs studied. Further, we examined the effect of FCGR SNPs on the incidence of the most
35 common CVID complications within our cohort: anaemias, organ-specific autoimmunity,
36 bronchiectasis, splenomegaly, granulomata, and cytopenias. We found no significant association
37 between SNPs and the development of these complications. In summary, we have shown that there is
38 a link between the *FCGR2A* H131R SNP and the development of a PID.

39

40 Keywords: primary immune deficiency; PID; common variable immunodeficiency disorders; CVID;
41 cytopenia; Fc gamma receptors

- 42 Funding information: SYP is funded by the Oxford NIHR Biomedical Research Centre, EWDF was
- 43 funded by the University of Oxford's Final Honours School.
- 44 Conflict of interest statement: The authors have no conflicts of interest to disclose.

45 Introduction

46 Fc γ receptors (Fc γ Rs) are glycoproteins, encoded on chromosome 1q23-24, which bind the Fc portion
47 of IgG[1, 2]. There are six human Fc γ Rs found on various immune cells which, when ligated,
48 modulate the immune response[2]. Fc γ Rs vary in structure and function, and are classified according
49 to their affinity for IgG immune complexes. The high-affinity Fc γ RI (CD64) binding monomeric IgG,
50 and the low-affinity receptors, Fc γ RIIa (CD32a), Fc γ RIIb (CD32b), Fc γ RIIc (CD32c), Fc γ RIIIa
51 (CD16a) and Fc γ RIIIb (CD16b)[2-5]. Engagement of the Fc γ Rs results in cellular activation, with the
52 exception of Fc γ RIIb, which is the sole inhibitory receptor. Immune cell activation is balanced by the
53 relative engagement of the activating and inhibiting low affinity Fc γ Rs, with immune dysregulation
54 and autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis
55 resulting from disrupting this balance[1].

56

57 There are three single nucleotide polymorphisms (SNPs) within the low-affinity receptors widely
58 reported to affect receptor function upon IgG binding[1]. These are located in the genes *FCGR2A*,
59 *FCGR2B*, and *FCGR3A* which encode Fc γ RIIa, Fc γ RIIb, and Fc γ RIIIa, respectively[6-8]. In
60 *FCGR2A*, a histidine (H) to arginine (R) SNP (rs1801274) at amino acid 131
61 (NM_001136219.3(FCGR2A):c.500A>G (p.His131Arg)), in which the H variant confers higher
62 affinity for IgG than the R variant, particularly IgG2[9]. An isoleucine (I) to threonine (T) SNP
63 (rs1050501) is located at amino acid 232 in *FCGR2B* (NM_004001.4(FCGR2B):c.695T>C
64 (p.Ile232Thr)), with the T variant inhibiting the receptor associating with lipid rafts in the cell
65 membrane, reducing inhibition of B cell receptor signalling[10, 11]. Additionally, polymorphisms
66 within the promoter region of *FCGR2B* have been linked to altered receptor expression and
67 autoimmunity[12]. In *FCGR3A*, a phenylalanine (F) to valine (V) SNP (rs39699) at amino acid 158
68 (NM_001127593.1(FCGR3A):c.526T>G (p.Phe158Val)), increases the receptor's affinity for IgG[6].
69 Copy number variants affecting this locus have also been described and reported to affect disease
70 susceptibility[10, 13-16].

71

72 These SNPs are associated with an increased risk of developing autoimmune diseases. The high
73 affinity *FCGR2A* 131H variant is associated with childhood-onset immune thrombocytopenic purpura
74 (ITP), rheumatoid arthritis, and Kawasaki disease[17-19]. Similarly, the high affinity *FCGR3A* 158V
75 variant is associated with both childhood- and adult-onset ITP[18, 20]. No clear pathological
76 mechanism has been established, however variants which confer higher affinity for ligand may lead to
77 greater immune cell activation, and thus autoimmunity. The inhibitory FcγRIIb receptor low affinity
78 *FCGR2B* 232T variant has been associated with ITP and SLE[21-23]. In SLE the decreased inhibitory
79 activity alters the germinal centre's control of peripheral tolerance which is proposed to lead to the
80 hyper-activation of the PI3K pathway, leading to the hyper-reactive features[24, 25].

81

82 Primary immunodeficiencies (PIDs) are a heterogeneous group of rare disorders characterised by poor
83 or absent function of at least one immune system component. Common variable immunodeficiency
84 disorders (CVID), a subtype of PID, is characterised by a marked decrease in IgG and at least one of
85 IgM or IgA, poor antibody response to vaccination, and an onset after 2 years of age, in the absence of
86 other causes of immunodeficiency[26, 27]. CVID has an estimated prevalence of 1 in 25,000 and is
87 the most common symptomatic antibody deficiency disorder[28, 29]. The aetiology of CVID is not
88 fully understood[30]. A genome-wide association study, and our whole genome sequencing study, of
89 patients with CVID both concluded that CVID is a polygenic disease[31, 32]. Patients with CVID can
90 be broadly classed as either infections only or complex. All patients experience recurrent infections,
91 particularly sinopulmonary infections, which often results in bronchiectasis[33]. Those with complex
92 CVID develop disease-related complications, including autoimmunity, cytopenias, granulomatous
93 disease and/or malignancy[34, 35]. The reduction but not absence in IgG and the presence of
94 antibody-mediated autoimmune disease complications in some patients, suggest CVID as a disease of
95 quality as well as quantity of antibody response. With the little antibody that is made possibly
96 recognising self-antigen.

97

98 Given (1) that Fc γ R polymorphisms have been shown to modify the risk of autoimmune diseases and
99 (2) the incidence of autoimmune complications of CVID is about 20%, including autoantibody-
100 mediated conditions such as ITP and autoimmune haemolytic anaemia (5-8%), we hypothesise that
101 Fc γ R polymorphisms may modify the disease course in CVID[36].

102 This study aims to:

- 103 1. Investigate the carriage of autoimmunity-associated Fc γ R SNPs in a cohort of patients with
104 PID, compared to immunocompetent controls.
- 105 2. Identify whether or not there is an association with autoimmunity-associated Fc γ R SNPs and
106 the development of CVID disease-related complications.

107 Materials and Methods

108 **Subjects:** DNA of 83 patients with PIDs was available for analysis. These patients were attending the
109 Clinical Immunology outpatient department, John Radcliffe Hospital, Oxford, UK at the time of
110 sampling. Whilst the primary focus of this study is CVID patients (n=56), other PID patients (n=27)
111 were included as non-CVID controls. Many of these patients had clinically validated genetic
112 diagnoses as well as disease-related complications such as cytopenias (**Table 1** and Supplementary
113 Table 1). Diagnosis of CVID was made in accordance to the ESID guidelines[37], with patients being
114 classified as infections only in the absence of any other complication. Patients were diagnosed with
115 cytopenia if leukocytes or platelets were below the normal range for more than 6 months outside
116 treatment for infection. The underlying causes of anaemia were further explored if unlikely to be PID-
117 related. Pancytopenia was defined as all three lineages (erythrocytes, platelets, and leukocytes) below
118 the normal range for ≥ 6 months. Other relevant clinical conditions were noted from patient notes. Our
119 in-house control group consisted of 48 anonymous, healthy volunteers from Oxfordshire, UK. All
120 individuals gave informed written consent. Studies were performed according to the Declaration of
121 Helsinki with South Central Research Ethics Committee approval (12/SC/0044) for patient
122 recruitment. Controls were recruited from the University of Oxford's Nuffield Department of
123 Medicine through the Oxford Gastrointestinal Illness Biobank (16/YH/0247).

124 **Control cohorts:** We calculated the Hardy-Weinberg equilibrium (HWE) using a Chi Squared test for
125 all groups compared to previously published genotype frequencies and found that the patient and
126 control group of *FCGR2A* were not within HWE ($p = 0.014$ and $p = 0.003$ respectively) (**Table**
127 **2**)[38]. To ensure a fair control group we supplemented our in-house controls with data on the same
128 three SNPs, genotyped by the same methods, in a large previously published cohort, also shown in
129 **Table 2**[39, 40]. All control groups were now within HWE and only the *FCGR2A* patient group was
130 not ($p = 0.014$). The power, calculated from previously published population allele frequencies,
131 equalled 1.000 for all three receptors[38].

132 **Laboratory analysis:** gDNA samples were isolated from patient peripheral blood mononuclear cell
133 samples using the Monarch Genomic DNA Purification Kit (New England Biolabs, UK) according to

134 manufacturer's instructions. Samples were analysed at three loci for the SNPs
135 NM_001136219.3(FCGR2A):c.500A>G (p.His167Arg), NM_004001.4(FCGR2B):c.695T>C
136 (p.Ile232Thr), and NM_001127593.1(FCGR3A):c.526T>G (p.Phe176Val) using a previously
137 published TaqMan method[41]. Primers, probes, and cycling conditions are shown in Supplementary
138 Table 2. The data was analysed using the BioRad manager software.

139 **Polymerase Chain Reaction (PCR) amplification:** Samples were amplified using the Applied
140 Biosystems 2720 Thermal Cycler (Applied Biosystems, CA, USA). Each reaction well contained:
141 1µL gDNA 5ng/µL, 12.5µL 2X GoTaq G2 Hot Start Green Master Mix (M7422, Promega, UK), 1µL
142 forward primer 10µM (Invitrogen, UK), 1µL reverse primer 10µM (Invitrogen, UK), 1µL de-ionised
143 H₂O. Primer design is shown in Supplementary Table 3. Touchdown PCR was used with cycling
144 conditions shown in Supplementary Table 4. Amplification was confirmed by gel electrophoresis.

145 **Gel electrophoresis:** A 1X Tris-Acetate-EDTA buffer gel with 1% agarose was prepared with a
146 0.01% Diamond Nucleic Acid Stain (Promega, UK). PCR samples were diluted 1 in 10 with de-
147 ionised H₂O; these were mixed with 6X DNA Loading Dye (Thermo Scientific, UK). The samples
148 were run for 2 hours at 110V, the Quick-Load Purple 1kb Plus Ladder (New England Biolabs, UK)
149 was used. Samples were then imaged using the ChemiDoc UV imager (Bio-Rad Laboratories, CA,
150 USA). A single clear band at the correct number of base pairs (*FCGR2A*: 627bp, *FCGR2B*: 751bp,
151 *FCGR3A*: 927bp) was taken as confirmation of amplification.

152 **Sanger sequencing:** Samples were purified using the Monarch PCR & DNA Cleanup Kit (5µg) (New
153 England Biolabs, UK) according to manufacturer's instructions, using 20µL of PCR product and
154 10µL of elution buffer. A NanoDrop 1000 (Thermo Fisher Scientific, MA, USA) full spectrum
155 spectrophotometer was used to determine the concentration of each sample. Samples were diluted
156 with de-ionised H₂O to a concentration of 5-20ng/µL. The samples were Sanger sequenced at the
157 MRC Weatherall Institute of Molecular Medicine (UK). Primer designs are shown in Supplementary
158 Table 3. Analysis was performed using FinchTV. For seven samples, the Sanger sequence result
159 differed from the TaqMan result. The TaqMan result was used for the *FCGR2A* and *FCGR2B* samples
160 and the Sanger sequencing result in the *FCGR3A* samples per findings of Hargreaves et al.

161 demonstrating superiority of the TaqMan assays for *FCGR2A* and *FCGR2B*, and the Sanger
162 sequencing assay for *FCGR3A*[41]. For *FCGR2B* this is due to the presence of known SNPs at the
163 Sanger sequencing probe binding sites which have been shown to disrupt the Sanger sequencing
164 results and report an over-representation of the *FCGR2B*-232T allele compared to previously
165 published frequencies[10, 41, 42]. One sample for *FCGR3A* was not included in the study due to
166 Sanger sequencing returning an inconclusive result. The decision-making process is shown in
167 Supplementary Figure 1.

168 **Statistics:** IBM SPSS Statistics (Version 27) was used to perform Chi Squared tests; R (Version
169 4.0.3, pwr package 1.3-0) was used to perform power calculations. Excel (Microsoft Office) was used
170 to calculate Hardy-Weinberg equilibrium. For all tests, $p < 0.05$ was considered significant.

171 Results

172 ***FCGR2A*-131H/H is under-represented amongst PID patients**

173 Altered genotype frequencies of *FCGR2A*-R131H have been found in different patient groups as
174 compared to controls. Specifically, an increased prevalence of the 131H allele is associated with an
175 increased risk of diseases, including Kawasaki disease and ITP[17, 18]. We sought to establish the
176 allele frequency amongst patients with CVID in comparison to patients with other PIDs, in-house
177 immunocompetent controls and a previously published cohort of immunocompetent patients
178 undergoing cancer immunotherapy[40].

179 For *FCGR2A*-131H/R we found a significant difference between genotype distribution in patients
180 with a PID and controls ($p=0.019$), but no significant difference in allele frequencies ($p=0.231$)
181 (**Table 3**). This difference was a decrease in the 131H/H genotype and a corresponding increase in the
182 heterozygous 131H/R genotype amongst all PID patients, compared to immunocompetent controls.
183 Subgroup analysis showed that this significant difference in genotype distribution was driven by the
184 mixed non-CVID PID group ($p=0.004$) but not the CVID cohort ($p=0.124$) when compared to our
185 control group (**Table 4**).

186 There was a statistically significant difference between the genotype distribution of the mixed non-
187 CVID PID group and the CVID group ($p=0.039$), with the 131R/R genotype making up 30.2% of
188 CVID patients compared to just 10.7% of non-CVID PID patients (**Table 4**). There was no significant
189 difference in allele frequencies upon any subgroup analysis (**Table 4**).

190 Further subgroup analysis of genotype and allele distribution based upon clinical phenotypes found no
191 significant differences (**Table 5**).

192 **In PID patients there was no significant difference in *FCGR2B*-232I/T and *FCGR3A*-158F/V** 193 **compared to controls**

194 Altered genotype frequencies of *FCGR2B*-232I/T and *FCGR3A*-158F/V have been found in patient
195 groups compared with controls. The low affinity 232T variant has been associated with an increased

196 risk of ITP and SLE[21-23]. Whilst the high affinity 158V variant has been shown to be associated
197 with both childhood- and adult-onset ITP[18, 20]. We sought to establish the allele frequency
198 amongst patients with CVID in comparison to patients with other PIDs, in-house immunocompetent
199 controls and a previously published cohort of immunocompetent patients undergoing cancer
200 immunotherapy[40].

201 For both *FCGR2B*-232I/T and *FCGR3A*-158F/V we found no significant difference in genotype
202 distribution ($p=0.260$, $p=0.659$) or allele frequencies ($p=0.235$, $p=0.573$) compared to controls (**Table**
203 **3**). Subgroup analysis breaking down the PID population into CVID, non-CVID and CMC groups
204 also yielded no significance in either genotype distribution or allele carriage (**Table 4**) and neither did
205 analysis based upon clinical phenotype (**Table 5**).

206 Discussion

207 The clinical significance of low affinity FcγR in disease has been investigated by various groups over
208 the last 20 years[43]. Previous studies in Kawasaki disease and ITP found that the *FCGR2A*-131R/R
209 genotype is linked with increased disease risk[17, 18]. The mechanisms behind this association have
210 not been explored. However, due to the differing affinities between these receptors it leads to
211 variation in the clearing of immune complexes, antigen presentation, and antibody mediated
212 phagocytosis all of which play a role in autoimmune diseases[20]. It is possible that the greater
213 proportion of the high affinity allele could result in an increased clearance of IgG sensitized cells.
214 Thus, leading to an overactivation of the immune system which could cause autoimmune attacks
215 which impair aspects of the immune system, causing a PID to develop.

216 We found no association between *FCGR2A* polymorphisms and CVID incidence rates ($p=0.124$).
217 Although our data did support an association between *FCGR2A* polymorphism and the presence of
218 any PID compared to control ($p=0.004$). This association was a decrease in the proportion of the high
219 affinity 131H/H receptor within the patient group compared to controls. Whilst this has not been
220 previously explored, the finding was interesting given the opposite previous findings in ITP and
221 Kawasaki's disease[17, 18]. Due to the relatively small non-CVID cohort we were unable to further
222 explore this association, however, this result does imply that the mechanism driving low platelet
223 counts could differ between CVID and non-CVID ITP. Also, given the majority of non-CVID PIDs
224 within our patient cohort had CMC (Supplementary Table 1) there is a possibility that this
225 polymorphism is linked to inhibition of the Th17 and Th1 immune cell pathways which have
226 previously been implicated in CMC progression[44]. To prove such a link would require further
227 research into the area.

228 We found no significant differences between the CVID and PID cohorts and controls in both
229 *FCGR2B* ($p=0.260$) and *FCGR3A* ($p=0.659$). This may be due to *FCGR2B* and *FCGR3A* not
230 contributing to pathology in this cohort, or our it could be that our cohort is simply too small to detect
231 an association driven by these variants.

232 We supplemented our controls with data collected from Strefford et al[40]. The patients involved in
233 this study were being treated with either obinutuzumab- or rituximab-chemotherapy for untreated
234 follicular lymphoma and diffuse large B-cell lymphoma in the GALLIUM and GOYA trials[45, 46].
235 While the cohort are not healthy individuals; the median age of patients in these studies
236 (GALLIUM=59 years, GOYA=62 years) was significantly higher than the typical age of diagnoses
237 for CVID (20-40 years) or other PIDs (median 9.5 years)[47, 48]. It is therefore unlikely that
238 undiagnosed PID cases could be within the reference control cohort. Fc γ R genetics have never been
239 demonstrated to predispose to cancer, and indeed the genotype frequencies were within expected
240 frequencies for this cohort, suggesting there was no selection pressure as demonstrated amongst
241 autoimmune cohorts. Furthermore, neither cancer is directly linked to the presence of a PID and
242 therefore for our purposes these patients form a suitable control group.

243 When comparing the Sanger sequence traces to the TaqMan data there were occasional discrepancies
244 between the two readouts. For both *FCGR2A* and *FCGR2B* we prioritised the readout from the
245 TaqMan assays as this has been previously validated[41]. For *FCGR3A*, there is copy number
246 variation which can complicate distinguishing FFV and FVV genotypes from FV[13]. Sanger
247 sequencing is less affected, providing the sequence from each allele can be detected, and thus this was
248 prioritised in cases of discrepancy[41].

249 **Study limitations**

250 The small sample size was a limitation of this study, especially within the non-CVID patient cohort,
251 as this limited the analysis which could be performed on the statistically significant difference found
252 at the *FCGR2A* SNP. The number of different diseases present within the non-CVID patients
253 (Supplementary Table 1) is also potentially problematic given that the different genetic make-up of
254 each disease could affect the Fc γ Rs differently.

255 A further limitation of the study is the discrepancies present between our TaqMan and Sanger
256 sequencing results. We are not sure why we had a higher rate of discrepancy than researchers who
257 have previously used the same methodology[40]. However, to mitigate the effect of these

258 discrepancies future work could involve the Sanger sequencing of a larger percentage of samples.
259 Given that in both *FCGR2A* and *FCGR3A* it was the same patient sample which was discordant this
260 could be due to a case of individual genetic variation, rather than a systemic issue. Finally, a repeat of
261 the genotyping using a different set of primers could lead to a set of concordant results. For instance, a
262 nested PCR protocol could lead to increased consistency in results due to its potential for higher
263 sensitivity and specificity[49].

264 **Further work**

265 This work could be expanded upon by increasing patient numbers, particularly the number of non-
266 CVID patients, and exploring a wider range of PID related complications. Doing so could allow for a
267 greater insight to the rare *FCGR2B*-232T/T genotype, as well as the rarer complications observed.
268 However, given that PIDs are rare diseases, this would certainly require collaboration with a group(s)
269 from a different geographical area as we were able to access samples from the majority of consenting
270 PID patients who have lived within the John Radcliffe catchment area in the last decade.
271 Alternatively, given the increasing number of PID patients who have undergone whole genome
272 sequencing this could be an avenue for further analysis of the FcγR SNPs mentioned[32].

273 Further, we did not consider the remaining two low affinity FcγRs: *FCGR2C* and *FCGR3B*. Both
274 genes contain disease-associated SNPs and copy number variations[50]. These differences have been
275 shown in previous studies to play a role in immune diseases such as SLE and ITP and thus may
276 potentially play a role in CVID development given their expression on natural killer cells and
277 neutrophils, something that could be explored in future research[3, 51, 52].

278 **Conclusions**

279 In summary, our results show that there is no significant genetic role of SNPs on the *FCGR2A*,
280 *FCGR2B*, and *FCGR3A* genes in CVID. We have shown that these SNPs both do not affect the risk of
281 developing CVID and are also not implicated in an increased risk of developing any of the most
282 common complications. We found evidence suggesting that *FCGR2A* may play a role in the
283 development of PIDs, but further studies of these FcγR SNPs are needed to confirm this finding.

284 Ethics Statement: Control and patient blood samples and gDNA were collected and stored with
285 written informed consent.

286

287 Author Contributions: EWDF performed experiments, analysed data and wrote the manuscript; JEGC
288 collected clinical information; CEH and SYP conceived and designed the study, supervised the study
289 and wrote the manuscript. All authors critically reviewed and approved the final version of the
290 manuscript.

291

292 Acknowledgements: The authors would like to acknowledge Alex Adams, Translational
293 Gastroenterology Unit, Nuffield Department of Medicine for statistical advice.

294

295 Conflict of interest statement: The authors have no conflicts to declare.

296 References

- 297 1 Hargreaves CE, Rose-Zerilli MJ, Machado LR *et al.* *Fcγ receptors: genetic variation,*
298 *function, and disease.* Immunological Reviews. 2015;268:6-24.
- 299 2 Ravetch JV. *Fc receptors: Rubor redux.* Cell. 1994 1994/08/26;78:553-60.
- 300 3 Vogelpoel LT, Baeten DL, de Jong EC, den Dunnen J. *Control of cytokine production by*
301 *human fc gamma receptors: implications for pathogen defense and autoimmunity.* Front Immunol.
302 2015;6:79.
- 303 4 Kuijpers T. *Fc-dependent mechanisms of action: roles of FcγR and FcRn.* Clin Exp Immunol.
304 2014 Dec;178 Suppl 1:89-91.
- 305 5 Nimmerjahn F, Ravetch JV. *Fc gamma receptors as regulators of immune responses.* Nat Rev
306 Immunol. 2008 Jan;8:34-47.
- 307 6 Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. *Fc gammaRIIIa-*
308 *158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa,*
309 *independently of the Fc gammaRIIIa-48L/R/H phenotype.* Blood. 1997 Aug 1;90:1109-14.
- 310 7 Warmerdam PA, van de Winkel JG, Gosselin EJ, Capel PJ. *Molecular basis for a*
311 *polymorphism of human Fc gamma receptor II (CD32).* J Exp Med. 1990 Jul 1;172:19-25.
- 312 8 Li X, Wu J, Carter RH *et al.* *A novel polymorphism in the Fc gamma receptor IIB (CD32B)*
313 *transmembrane region alters receptor signaling.* Arthritis Rheum. 2003 Nov;48:3242-52.
- 314 9 Parren PW, Warmerdam PA, Boeije LC *et al.* *On the interaction of IgG subclasses with the*
315 *low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a*
316 *functional polymorphism to human IgG2.* J Clin Invest. 1992 Oct;90:1537-46.
- 317 10 Floto RA, Clatworthy MR, Heilbronn KR *et al.* *Loss of function of a lupus-associated*
318 *Fc gammaRIIb polymorphism through exclusion from lipid rafts.* Nat Med. 2005 Oct;11:1056-8.
- 319 11 Kono H, Kyogoku C, Suzuki T *et al.* *Fc gammaRIIb Ile232Thr transmembrane polymorphism*
320 *associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates*
321 *inhibitory effects on B cell receptor signaling.* Hum Mol Genet. 2005 Oct 1;14:2881-92.
- 322 12 Su K, Wu J, Edberg JC *et al.* *A promoter haplotype of the immunoreceptor tyrosine-based*
323 *inhibitory motif-bearing Fc gammaRIIb alters receptor expression and associates with autoimmunity.*
324 *I. Regulatory FCGR2B polymorphisms and their association with systemic lupus erythematosus.* J
325 Immunol. 2004 Jun 1;172:7186-91.
- 326 13 Niederer HA, Willcocks LC, Rayner TF *et al.* *Copy number, linkage disequilibrium and*
327 *disease association in the FCGR locus.* Hum Mol Genet. 2010 Aug 15;19:3282-94.
- 328 14 Willcocks LC, Lyons PA, Clatworthy MR *et al.* *Copy number of FCGR3B, which is*
329 *associated with systemic lupus erythematosus, correlates with protein expression and immune*
330 *complex uptake.* J Exp Med. 2008 Jul 7;205:1573-82.
- 331 15 Fanciulli M, Norsworthy PJ, Petretto E *et al.* *FCGR3B copy number variation is associated*
332 *with susceptibility to systemic, but not organ-specific, autoimmunity.* Nat Genet. 2007 Jun;39:721-3.
- 333 16 Mueller M, Barros P, Witherden AS *et al.* *Genomic pathology of SLE-associated copy-*
334 *number variation at the FCGR2C/FCGR3B/FCGR2B locus.* Am J Hum Genet. 2013 Jan 10;92:28-40.
- 335 17 Khor CC, Davila S, Breunis WB *et al.* *Genome-wide association study identifies FCGR2A as*
336 *a susceptibility locus for Kawasaki disease.* Nat Genet. 2011 Nov 13;43:1241-6.
- 337 18 Carcao MD, Blanchette VS, Wakefield CD *et al.* *Fc gamma receptor IIa and IIIa*
338 *polymorphisms in childhood immune thrombocytopenic purpura.* Br J Haematol. 2003 Jan;120:135-
339 41.
- 340 19 Lee YH, Bae SC, Song GG. *FCGR2A, FCGR3A, FCGR3B polymorphisms and susceptibility*
341 *to rheumatoid arthritis: a meta-analysis.* Clin Exp Rheumatol. 2015 Sep-Oct;33:647-54.
- 342 20 Pavkovic M, Petlichkovski A, Karanfilski O, Cevreska L, Stojanovic A. *FC gamma receptor*
343 *polymorphisms in patients with immune thrombocytopenia.* Hematology. 2018 Apr;23:163-8.
- 344 21 Chu ZT, Tsuchiya N, Kyogoku C *et al.* *Association of Fc gamma receptor IIB polymorphism*
345 *with susceptibility to systemic lupus erythematosus in Chinese: a common susceptibility gene in the*
346 *Asian populations.* Tissue Antigens. 2004 Jan;63:21-7.
- 347 22 Hu W, Zhang Y, Sun X *et al.* *FcγRIIB-I232T polymorphic change allosterically suppresses*
348 *ligand binding.* Elife. 2019 Jul 25;8.

- 349 23 Wu Z, Zhou J, Prsoon P, Wei X, Liu X, Peng B. *Low expression of FCGR1B in macrophages*
350 *of immune thrombocytopenia-affected individuals*. Int J Hematol. 2012 Nov;96:588-93.
- 351 24 Xu L, Li G, Wang J *et al*. *Through an ITIM-independent mechanism the FcγRIIB blocks B*
352 *cell activation by disrupting the colocalized microclustering of the B cell receptor and CD19*. J
353 Immunol. 2014 Jun 1;192:5179-91.
- 354 25 Weisenburger T, von Neubeck B, Schneider A *et al*. *Epistatic Interactions Between Mutations*
355 *of Deoxyribonuclease 1-Like 3 and the Inhibitory Fc Gamma Receptor IIB Result in Very Early and*
356 *Massive Autoantibodies Against Double-Stranded DNA*. Front Immunol. 2018;9:1551.
- 357 26 Bousfiha A, Moundir A, Tangye SG *et al*. *The 2022 Update of IUIS Phenotypical*
358 *Classification for Human Inborn Errors of Immunity*. Journal of Clinical Immunology. 2022
359 2022/10/01;42:1508-20.
- 360 27 Conley ME, Dobbs AK, Farmer DM *et al*. *Primary B Cell Immunodeficiencies: Comparisons*
361 *and Contrasts*. Annual Review of Immunology. 2009;27:199-227.
- 362 28 Bonilla FA, Barlan I, Chapel H *et al*. *International Consensus Document (ICON): Common*
363 *Variable Immunodeficiency Disorders*. The Journal of Allergy and Clinical Immunology: In Practice.
364 2016 2016/01/01;4:38-59.
- 365 29 Cunningham-Rundles C, Maglione PJ. *Common variable immunodeficiency*. J Allergy Clin
366 Immunol. 2012 May;129:1425-6.e3.
- 367 30 de Valles-Ibáñez G, Esteve-Solé A, Piquer M *et al*. *Evaluating the Genetics of Common*
368 *Variable Immunodeficiency: Monogenetic Model and Beyond*. Front Immunol. 2018;9:636.
- 369 31 Orange JS, Glessner JT, Resnick E *et al*. *Genome-wide association identifies diverse causes*
370 *of common variable immunodeficiency*. J Allergy Clin Immunol. 2011 Jun;127:1360-7.e6.
- 371 32 van Schouwenburg PA, Davenport EE, Kienzler A-K *et al*. *Application of whole genome and*
372 *RNA sequencing to investigate the genomic landscape of common variable immunodeficiency*
373 *disorders*. Clinical Immunology. 2015 2015/10/01;160:301-14.
- 374 33 Ramzi N, Jamee M, Bakhtiyari M *et al*. *Bronchiectasis in common variable*
375 *immunodeficiency: A systematic review and meta-analysis*. Pediatr Pulmonol. 2020 Feb;55:292-9.
- 376 34 Cunningham-Rundles C. *The many faces of common variable immunodeficiency*. Hematology
377 Am Soc Hematol Educ Program. 2012;2012:301-5.
- 378 35 Chapel H, Lucas M, Lee M *et al*. *Common variable immunodeficiency disorders: division*
379 *into distinct clinical phenotypes*. Blood. 2008 Jul 15;112:277-86.
- 380 36 Agarwal S, Cunningham-Rundles C. *Autoimmunity in common variable immunodeficiency*.
381 Curr Allergy Asthma Rep. 2009 Sep;9:347-52.
- 382 37 Edgar D, Ehl S. *ESID Registry-Working definitions for clinical diagnosis of PID, 2014*.
383 Google Scholar.1-33.
- 384 38 Nagelkerke SQ, Tacke CE, Breunis WB *et al*. *Extensive Ethnic Variation and Linkage*
385 *Disequilibrium at the FCGR2/3 Locus: Different Genetic Associations Revealed in Kawasaki Disease*.
386 Front Immunol. 2019;10:185-.
- 387 39 Chang C. *Statistical tests*. 2020 [cited; Available from: [https://www.cog-](https://www.cog-genomics.org/software/stats)
388 [genomics.org/software/stats](https://www.cog-genomics.org/software/stats)]
- 389 40 Strefford JC, Nowicka M, Hargreaves CE *et al*. *Single-nucleotide Fcγ receptor*
390 *polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma*. Blood
391 Adv. 2021 Aug 10;5:2935-44.
- 392 41 Hargreaves CE, Iriyama C, Rose-Zerilli MJ *et al*. *Evaluation of High-Throughput Genomic*
393 *Assays for the Fc Gamma Receptor Locus*. PLoS One. 2015;10:e0142379-e.
- 394 42 Li SS, Gilbert PB, Tomaras GD *et al*. *FCGR2C polymorphisms associate with HIV-1 vaccine*
395 *protection in RV144 trial*. J Clin Invest. 2014 Sep;124:3879-90.
- 396 43 Lehrnbecher T, Foster CB, Zhu S *et al*. *Variant genotypes of the low-affinity Fcγgamma*
397 *receptors in two control populations and a review of low-affinity Fcγgamma receptor polymorphisms*
398 *in control and disease populations*. Blood. 1999 Dec 15;94:4220-32.
- 399 44 Eyerich K, Eyerich S, Hiller J, Behrendt H, Traidl-Hoffmann C. *Chronic mucocutaneous*
400 *candidiasis, from bench to bedside*. Eur J Dermatol. 2010 May-Jun;20:260-5.
- 401 45 Marcus R, Davies A, Ando K *et al*. *Obinutuzumab for the First-Line Treatment of Follicular*
402 *Lymphoma*. N Engl J Med. 2017 Oct 5;377:1331-44.

- 403 46 Vitolo U, Trněný M, Belada D *et al.* *Obinutuzumab or Rituximab Plus Cyclophosphamide,*
404 *Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.* *J*
405 *Clin Oncol.* 2017 Nov 1;35:3529-37.
- 406 47 Herber M, Mertz P, Dieudonné Y *et al.* *Primary immunodeficiencies and lymphoma: a*
407 *systematic review of literature.* *Leuk Lymphoma.* 2020 Feb;61:274-84.
- 408 48 Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. *Morbidity and mortality in*
409 *common variable immune deficiency over 4 decades.* *Blood.* 2012 Feb 16;119:1650-7.
- 410 49 Green MR, Sambrook J. *Nested Polymerase Chain Reaction (PCR).* *Cold Spring Harb Protoc.*
411 2019 Feb 1;2019.
- 412 50 Erbe AK, Wang W, Gallenberger M, Hank JA, Sondel PM. *Genotyping Single Nucleotide*
413 *Polymorphisms and Copy Number Variability of the FCGRs Expressed on NK Cells.* *Methods Mol*
414 *Biol.* 2016;1441:43-56.
- 415 51 Kyogoku C, Dijkstra HM, Tsuchiya N *et al.* *Fcγ receptor gene polymorphisms in*
416 *Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic*
417 *susceptibility.* *Arthritis Rheum.* 2002 May;46:1242-54.
- 418 52 Breunis WB, van Mirre E, Bruin M *et al.* *Copy number variation of the activating FCGR2C*
419 *gene predisposes to idiopathic thrombocytopenic purpura.* *Blood.* 2008 Feb 1;111:1029-38.

420 Tables

	CVID patients (n=56)	non-CVID patients (n=27)
Age in years (mean)	62	45
Gender (female %)	50	48.1
CVID type		
Infections (%)†	28 (56)	-
Complex (%)†	22 (44)	-
Complications		
Anaemias (%)	21 (37.5)	4 (14.8)
Organ-Specific Autoimmunity (%)	11 (19.6)	2 (7.4)
Bronchiectasis (%)	27 (48.2)	8 (29.6)
Splenomegaly (%)	23 (41.1)	3 (11.1)
Granulomata (%)	14 (25.0)	2 (7.4)
Cytopenias (%)	20 (35.7)	5 (18.5)

421 **Table 1. Clinical characteristics of cohort studied.** †Phenotypic classification for 6 CVID patients was unable to be
422 determined.

Gene	Genotype	In-house Controls n (%)	Patients n (%)	Supplemented controls n (%)
<i>FCGR2A-131H/R</i>				
	131H/H	15 (31.3)	15 (18.1)	811 (32.3)
	131H/R	23 (47.9)	49 (59.0)	1169 (46.5)
	131R/R	10 (20.8)	19 (22.9)	533 (21.2)
HWE Chi Squared (p)		8.55 (0.003)	6.08 (0.014)	0.649 (0.421)
<i>FCGR2B-232I/T</i>				
	232I/I	39 (81.25)	68 (81.9)	1634 (74.6)
	232I/T	9 (18.75)	13 (15.7)	513 (23.4)
	232T/T	0 (0)	2 (2.4)	44 (2.0)
HWE Chi Squared (p)		2.51 (0.113)	(0.190) †	0.160 (0.688)
<i>FCGR3A-158F/V</i>				
	158F/F	18 (37.5)	41 (49.4)	1090 (43.4)
	158F/V	22 (45.8)	32 (38.6)	1119 (44.6)
	158V/V	8 (16.7)	10 (12.0)	301 (12.0)
HWE Chi Squared (p)		1.88 (0.170)	2.256 (0.133)	0.371 (0.543)

423 **Table 2. Genotype distributions and HWE calculations in patients with a PID, in-house control subjects, and total**
424 **supplemented control groups. Bold italic values are statistically significant. †There were fewer than 5 individuals within a**
425 **group so a HWE exact test was performed[39].**

Gene	Genotype	Patients n (%)	Controls n (%)	p-value (Chi Squared value)
<i>FCGR2A-131H/R</i>				
	131H/H	15 (18.1)	811 (32.3)	<i>.019 (7.884)</i>
	131H/R	49 (59.0)	1169 (46.5)	
	131R/R	19 (22.9)	533 (21.2)	
	131 H	64 (48.5)	1980 (53.8)	.231 (1.434)
	131 R	68 (51.5)	1702 (46.2)	
<i>FCGR2B-232I/T</i>				
	232I/I	68 (81.9)	1634 (74.6)	.260 (2.696)
	232I/T	13 (15.7)	513 (23.4)	
	232T/T	2 (2.4)	44 (2.0)	
	232 I	81 (84.4)	2147 (79.4)	.235 (1.411)
	232 T	15 (15.6)	557 (20.6)	
<i>FCGR3A-158F/V</i>				
	158F/F	41 (49.4)	1090 (43.4)	.659 (.833)
	158F/V	32 (38.6)	1119 (44.6)	
	158V/V	10 (12.0)	301 (12.0)	
	158 F	73 (63.5)	2209 (60.9)	.573 (.318)
	158 V	42 (36.5)	1420 (39.1)	

426 **Table 3. Genotype distributions and allele frequencies for patients with PIDs and controls.** Bold italic values are
427 statistically significant.

428

Gene	Groups being compared. A / B	Genotype breakdown of A / B n / n (%)/(%)			Genotype distribution p-value (Chi Squared value)	Allele carriage p-value (Chi Squared value)
FCGR2A-131H/R		131R/R	131R/H	131H/H		
	Control / CVID	532/16 (21.2)/(30.2)	1169/25 (46.5)/(47.2)	811/12 (32.3)/(22.6)	.124 (4.18)	.221 (1.50)
	Control / non-CVID	532/3 (21.2)/(10.7)	1169/22 (46.5)/(78.6)	811/3 (32.3)/(10.7)	.004 (10.8)	.681 (0.169)
	Control / CMC	532/1 (21.2)/(8.3)	1169/9 (46.5)/(75.0)	811/2 (32.3)/(16.7)	.142 (3.911)	.906 (0.014)
	CVID / non-CVID	16/3 (30.2)/(10.7)	25/22 (47.2)/(78.6)	12/3 (22.6)/(10.7)	.039 (6.47)	.643 (0.214)
FCGR2B-232I/T		232I/I	232I/T	232T/T		
	Control / CVID	1634/45 (74.6)/(84.9)	512/7 (23.4)/(13.2)	44/1 (2.0)/(1.9)	.216 (3.07)	.167 (1.91)
	Control / non-CVID	1634/21 (74.6)/(75.0)	512/6 (23.4)/(21.4)	44/1 (2.0)/(3.6)	.810 (0.421)	.865 (0.029)
	Control / CMC	1634/8 (74.6)/(66.7)	512/3 (23.4)/(25.0)	44/1 (2.0)/(8.3)	.294 (2.450)	.561 (0.338)
	CVID / non-CVID	45/21 (84.9)/(75.0)	7/6 (13.2)/(21.4)	1/1 (1.9)/(3.6)	.641 (0.889)	.425 (0.637)
FCGR3A-158F/V		158F/F	158F/V	158V/V		
	Control / CVID	1090/25 (43.4)/(47.2)	1118/20 (44.6)/(37.7)	301/8 (12.0)/(15.1)	.610 (0.989)	.710 (0.138)
	Control / non-CVID	1090/15	1118/11	301/2	.766 (0.533)	.652 (0.203)

	(43.4)/(53.6)	(44.6)/(39.3)	(12.0)/(7.1)		
Control / CMC	1090/6	1118/6	301/0	.441 (1.637)	.616 (0.252)
	(43.4)/(50.0)	(44.6)/(50.0)	(12.0)/(0.0)		
CVID / non-CVID	25/15	20/11	8/2	.908 (0.193)	.891 (0.019)
	(47.2)/(53.6)	(37.7)/(39.3)	(15.1)/(7.1)		

429 **Table 4. Genotype and allele carriage statistical differences between cohort groups.** Bold italic values are statistically

430 significant.

431

Gene	Complication	Genotype and number breakdown			Genotype distribution p-value (Chi-Squared value)	Allele carriage p-value (Chi-Squared value)
		n (%)				
<i>FCGR2A-</i>		131R/R	131R/H	131H/H		
	131H/R					
	Infections	11 (37.9)	12 (41.4)	6 (20.7)		
	Complex	4 (22.2)	9 (50.0)	5 (27.8)	.527 (1.282)	.520 (0.413)
	Anaemias	7 (29.2)	12 (50.0)	5 (20.8)	.622 (0.951)	.863 (0.0296)
	Organ-Specific Autoimmunity	1 (7.1)	8 (57.1)	5 (35.7)	.099 (4.625)	.272 (1.207)
	Bronchiectasis	10 (31.3)	15 (46.9)	7 (21.9)	.244 (2.825)	.779 (0.079)
	Splenomegaly	5 (21.7)	13 (56.5)	5 (21.7)	.890 (0.233)	.825 (0.049)
	Granulomata	3 (21.4)	9 (64.3)	2 (14.3)	.857 (0.308)	.686 (0.164)
	Cytopenias	6 (28.6)	11 (52.4)	4 (19.0)	.904 (0.202)	.822 (0.050)
<i>FCGR2B-</i>		232I/I	232I/T	232T/T		
	232I/T					
	Infections	25 (86.2)	3 (10.3)	1 (3.4)		
	Complex	14 (77.8)	4 (22.2)	0 (0)	.413 (1.768)	.564 (0.334)
	Anaemias	21 (87.5)	3 (12.5)	0 (0)	.532 (1.261)	.415 (0.663)
	Organ-Specific Autoimmunity	9 (64.3)	4 (28.6)	1 (7.1)	.152 (3.765)	.128 (2.319)
	Bronchiectasis	26 (81.3)	6 (18.8)	0 (0)	.461 (1.547)	.971 (0.001)
	Splenomegaly	18 (78.3)	5 (21.7)	0 (0)	.477 (1.482)	.743 (0.107)
	Granulomata	13 (92.9)	1 (7.1)	0 (0)	.467 (1.523)	.284 (1.149)
	Cytopenias	16 (76.2)	5 (23.8)	0 (0)	.570 (1.125)	.641 (0.217)
<i>FCGR3A-</i>		158F/F	158F/V	158V/V		
	158F/V					
	Infections	17 (58.6)	8 (27.6)	4 (13.8)		

Complex	6 (33.3)	9 (50.0)	3 (16.7)	.217 (3.055)	.327 (0.961)
Anaemias	11 (45.8)	7 (29.2)	6 (25.0)	.072 (5.249)	.469 (0.524)
Organ-Specific Autoimmunity	6 (42.9)	7 (50.0)	1 (7.1)	.570 (1.125)	.875 (0.025)
Bronchiectasis	17 (53.1)	10 (31.3)	5 (15.6)	.524 (1.292)	.879 (0.023)
Splenomegaly	10 (43.5)	8 (34.8)	5 (21.7)	.269 (2.625)	.469 (0.524)
Granulomata	4 (28.6)	9 (64.3)	1 (7.1)	.089 (4.848)	.443 (0.589)
Cytopenias	10 (47.6)	6 (28.6)	5 (23.8)	.228 (2.960)	.564 (0.333)

432 **Table 5. Analysis of complications development, broken down by SNP, within the PID cohort.**

433 Figure Legends

434 **Figure 1. TaqMan genotyping plots with gating strategy shown.** gDNA samples were genotyped
435 in triplicate for genes *FCGR2A*, *FCGR2B*, and *FCGR3A*. The reference alleles for each gene are
436 shown in orange circles, the alternate allele in blue squares and heterozygotes in green triangles and
437 non-template controls as black diamonds. Gates were manually drawn to genotype samples. Samples
438 which were not easily gated were confirmed by Sanger sequencing.




Figure 1. TaqMan

n genotyping plots with gating strategy shown. gDNA samples were genotyped in triplicate for genes *FCGR2A*, *FCGR2B* and *FCGR3A*. The reference alleles for each gene are shown in orange circles, the alternate allele in blue squares and heterozygotes in green triangles and non-template as black diamonds. Gates were manually drawn to genotype samples. Samples which were not easily gated were confirmed by Sanger sequencing.